AcuraStem Secures $7 Million in Funding Support from NIH and DOD to Accelerate Therapies for ALS and FTD

AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trials PASADENA, Calif., Jan. 30, 2024 /PRNewswire/ — AcuraStem, a patient-based biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS),…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks